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Insulin autoimmune syndrome (IAS) or Hirata’s disease is a rare disorder
characterized by hypoglycemia secondary to insulin autoantibodies (IAb).
Over 200 patients have been described from Japan with significantly less
numbers being reported from outside the Orient. IAS is more common in
patients older than 40 yr of age with reports in the pediatric age group being
notably rarer. Exposure to sulfhydryl group containing medications is
implicated in the pathogenesis of this syndrome. In this report, we describe a
case of IAS in an African-American adolescent. A 16-yr-old healthy
African-American male was diagnosed with Graves’ disease and started on
Methimazole. Four weeks later, he was found unconscious and hypoglycemic
(blood sugar 1.5 mmol/L). Evaluation was negative for insulinoma. Insulin
antibodies were positive. Oral glucose tolerance test revealed elevated free
insulin concentrations with disproportionately elevated total insulin levels.
The patient was started on prednisone, diazoxide, and propranolol for
management of IAS and hyperthyroidism. Thyroid radio-ablation was
subsequently undertaken. The doses of prednisone and diazoxide were tapered
and these medications discontinued after 9 months. The insulin antibody
levels decreased gradually and became undetectable in 6 months with
resolution of the hypoglycemia.
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Insulin autoimmune syndrome (IAS), or Hirata’s dis-
ease, is a rare disorder characterized by hypoglycemia
associated with insulin autoantibodies (IAb) in serum
(1). The first case report of IAS was documented by
Hirata in 1970 (2). IAS is the third leading cause
of hypoglycemia in Japan with over 200 cases being
reported (3). The incidence outside the Orient is sig-
nificantly less (1). The peak onset of this condition is
60–69 yr of age (4). Reports of this disorder in African-
Americans and in children are distinctly rare (1).
IAS is characterized by fasting and/or postprandial
hypoglycemia, high serum concentrations of total
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immunoreactive insulin, and presence of serum
polyclonal autoantibodies against insulin (2). It has
been strongly related with previous exposure to
sulfhydryl group containing medications, such as
Methimazole (MTZ), as well as to alpha lipoic acid
(3, 6, 10, 11, 12). The proposed mechanism of IAS
is that binding of insulin to the antibodies reduces
the availability of the secreted insulin, resulting in
hyperglycemia and further insulin secretion; once
blood glucose concentration begins to decrease and
endogenous insulin secretion declines, the unregulated
release of insulin bound to the antibodies results
in inappropriately high concentration of free insulin
and ensuing hypoglycemia (1). Furthermore, studies
suggest that insulin presented by HLA class II
molecules coded by DRBI*0406, DQAI*0301, and/or
DQB 1 *0302 induces T-lymphocyte proliferation in
IAS (5), suggesting that certain populations are at
higher risk. In the current report, we describe a rare
case of a MTZ-associated IAS in an African-American
adolescent.
Case report
A healthy 16-year-old African-American male was
diagnosed with Graves’ disease in summer 2010.
At diagnosis thyroid stimulating hormone level
was <0.01 mU/L (reference range: 0.3–5.5 mU/L),
Free T4 was 72 pmol/L (5.6 ng/dL, reference
range: 0.9–1.8 ng/dL), and total T3 was 7.9 nmol/L
(514 ng/dL, reference range: 60–181 ng/dL). In August
2010, he was started on MTZ 20 mg three times a day
(TID) and propranolol 10 mg TID. Four weeks after
starting MTZ, the patient experienced drowsiness and
fell asleep in the classroom. The following morning,
he was found unresponsive in his dormitory room.
Emergency medical service measured the blood sugar
level to be 1.5 mmol/L (27 mg/dL) and the patient
was treated with D50 bolus. Patient was transported
to a local emergency department. Upon arrival, he
presented with seizure and blood sugar level was
2.6 mmol/L (48 mg/dL). He was administered a second
bolus of D50 and was subsequently intubated for
airway protection. He received supplemental dextrose
for continued hypoglycemia, and was monitored in
the intensive care unit. Physical examination did not
reveal acanthosis nigricans and he was not obese (BMI
24 kg/m2). Evaluation upon admission was significant
with abnormal thyroid function tests consistent
with active Graves’ hyperthyroidism, and elevated
C-peptide and insulin levels suggestive of endogenous
hyperinsulinism. Laboratory tests to evaluate for an
infectious process, drug abuse, exogenous insulin,
and multiple endocrine neoplasias were unremarkable
(Table 1). Brain MRI was negative for masses or
hemorrhage.
At day 4 of presentation, repeated laboratory
tests for evaluation of hyperinsulinism was significant
for a high C-peptide level of 3.34 nmol/L (reference
range: 0.3–1.3 nmol/L) and high insulin level of
1184.5 pmol/L (reference range: 21.5–200.9 pmol/L).
Glucose level at that time, however, was 16.3 mmol/L
(295 mg/dL). The patient required D7.5–D10% in IV
fluids to maintain euglycemia. A trial of IV fluids
without dextrose was attempted; the blood glucose
dropped from 3.94 mmol/L (71 mg/dL) to 2.6 mmol/L
(48 mg/dL) within 12 min of discontinuation of
dextrose. Given the concern for IAS, Propylthiouracil
(PTU) was substituted for MTZ. Liver function tests
were monitored during his hospital stay and were
unremarkable. Abdominal ultrasound was negative
for tumor.
In addition to regular food intake, the patient
required IV infusion of D7.5–12% (GIR =
Table 1. Baseline endocrine profile
Laboratory test Result Reference range
Thyroid TSH 0.01 0.30–5.50 mIU/L
Free T4 28.7 9.7–21.8 pmol/L
Free T3 0.123 0.029–0.060 pmol/L
Total T3 4.6 1.23–2.69 pmol/L
Thyroid receptor antibodies 12 0.00–1.75 IU/L
Thyroid stimulating IG 1.5 <1.3
Adrenal Cortisol (04:00 hours) 154.4 193.1–606.8 nmol/L
ACTH 8.2 1.1–11.5 pmol/L
Parathyroid Intact parathyroid hormone 2.21 1.05–6.84 pmol/L
Total calcium 2.09 2.14–2.54 mmol/L
Pancreatic β-cell Insulin 438 7.175–150.6 pmol/L
C-peptide 3.8 0.33–1.7 nmol/L
Hemoglobin A1C 5.8 3.8–6.4%
Tumor markers Prolactin 7 3–23 μg/L
BHCG <2 <5 U/L
Gastrin 35.4 25.0–111.0 ng/L
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Insulin antibody (reference range: 0.00–0.02 nmol/L) was
measured by at the Mayo Clinic (MN).
Fig. 1. OGTT results.
1.9–4.1 mg/kg/min) to avoid hypoglycemia with
blood sugar levels ranging from 3.8 to 21.3 mmol/L
(69–385 mg/dL). Computerized-tomography with
optimized pancreas protocol was unremarkable. An
Octreotide scan showed no scintigraphic evidence of
insulinoma.
Insulin antibodies were evaluated due to suspicion
of IAS. Insulin antibodies obtained on day 4 of
presentation were significantly elevated at >50 unit/mL
(reference range: <0.4 unit/mL). Insulin antibodies
measured on days 7, 8, and 9 of presentation continued
to be significantly elevated (Table 2).
To further evaluate the relationship between the
serum concentrations of free insulin, total insulin,
glucose, and C-peptide levels, the patient underwent
an oral glucose tolerance test. A 75 g glucose load was
given to the patient and blood samples were obtained
every 30 min. The results of OGTT show that both free
and total insulin levels were significantly elevated at
all-time points (Fig. 1). Free insulin levels showed a
slight increase at 30 min. C-peptide level was also raised
at 30 min, but began to decline significantly by 90 min.
Total insulin level increased markedly at 30 min, and
declined slowly thereafter, but remained elevated above
baseline, suggesting a delay in the clearance of total
insulin.
Propranolol was used for the temporary control of
his tachycardia. Persistent hypoglycemia was managed
with prednisone and diazoxide. The patient underwent
thyroid radio-ablation therapy. Six months later,
IAB levels decreased to normal levels (0.01 nmol/L)
and the medications were gradually weaned. The
hypoglycemia has not recurred and he continues
to receive levothyroxine replacement therapy for
iatrogenic hypothyroidism.
Discussion
IAS is a rare cause of hypoglycemia which has
been described mainly in the adult population with
the majority of cases being reported from Japan
(7). The current report highlights the possibility of
this syndrome occurring in children and in African-
Americans. The cause of IAS is not completely
understood. Autoimmune disorders, previous expo-
sure to alpha lipoic acid or sulfhydryl medications
(such as MTZ), and certain HLA types have been
implicated in the etiology of this syndrome. It has been
hypothesized that sulfhydryl group drugs may cleave
the disulfide bond of insulin molecule in vivo and
enhance its immunogenicity (11). In some cases discon-
tinuing sulfhydryl medication was found to correlate
with remission, while re-introducing it was associated
with recurrence of hypoglycemia (1). However, in
vitro experiments involving incubation of insulin with
sulfhydryl group drugs failed to demonstrate an effect
on the insulin structure or immunoreactivity (1, 12). In
our patient, the history of exposure to MTZ supports
an etiological role for drugs with sulfhydryl group
drugs in the development of IAS.
A striking feature of this patient’s presentation was
the extremely high levels of circulating insulin. This
degree of elevated insulin in a patient with hypo-
glycemia would be suggestive of circumstances such
as iatrogenic administration of insulin, insulinoma,
or autoimmune syndromes including IAS and anti-
insulin receptor antibodies (type B insulin resistance
syndrome). Although insulin receptor antibodies were
not measured, type B insulin resistance is unlikely.
Rare cases of patients presenting with both insulin
and insulin receptor antibodies have been reported
(13); however, no new cases have been seen since the
introduction of human insulin (1).
In IAS total insulin levels are markedly elevated,
usually above 100 μU/mL (717.5 pmol/L) (1). In order
to evaluate free and total insulin levels, 3-h OGTT
was performed. Total insulin levels (free + bound
insulin) were significantly elevated at all time points
(Fig. 1). These increased markedly at 30 min, and
declined slowly thereafter, but remained elevated above
baseline. Free insulin levels showed a slight increase at
30 min and a slight decline after 90 min. The persistent
elevation and slow decline of the total insulin levels as
well as the elevated levels of serum insulin antibodies
are consistent with IAS. The insulin antibodies done
on day 4 of presentation were measured to Specialty
Laboratories. The insulin antibodies obtained on
days 7, 8, and 9 of presentation were measured to
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Mayo Clinic Laboratory. Both laboratories used the
radioimmunoassay method, although reference ranges
are different.
Our patient was started on prednisone on day 7 of
presentation and diazoxide on day 13 of presentation
for suspected IAS. The potential benefits of prednisone
included (i) elevation of blood sugar via insulin
resistance; (ii) suppression of autoimmunity; and (iii)
inhibition of conversion of T4 to T3. Stabilization
of blood glucose levels was observed concurrently
with discontinuation of MTZ and initiation of
prednisone therapy. Further improvement in blood
glucose without recurrence of hypoglycemia occurred
once diazoxide was started. The mechanism for IAS
resolution is unclear, but could be related to many
factors including discontinuation of MTZ, initiation of
prednisone therapy, and natural course of the disease.
This patient presented with minimally low cortisol
level with normal ACTH level on day 7 of presentation
(Table 1), although cortisol level was normal on day
1 of presentation (413.85 nmol/L, reference range:
118.6–623.5). Low cortisol level in the presence of
hypoglycemia could be seen in patients with Addison’s
disease. However, since the ACTH level was not
elevated and there was absence of overt signs such
as mucosa hyperpigmentation to suggest Addison’s
disease, we judged this possibility to be very unlikely.
His low cortisol level was more likely due to inadequate
sleep because of the hospital setting or hyperthyroidism
(14). Morning cortisol level 4 weeks after discontinuing
prednisone therapy was within the normal range
(331 nmol/L, reference range: 118.6–626.2 nmol/L).
Propranolol was started on inpatient day 17 due to
tachycardia and systolic hypertension (blood pressure
ranging 131-139/67-73). Although using propranolol
in the presence of hypoglycemia can be risky because
of its masking effect in the sympathetic response to
hypoglycemia (15), remission of hypoglycemia had
occurred 5 d prior to starting propranolol. He moni-
tored his blood glucose four times a day and he did not
experience any recurrent hypoglycemia. Propranolol
was discontinued after thyroid ablation therapy.
In summary, we report a rare case of IAS in an
African-American adolescent. IAS should be consid-
ered in the differential diagnosis of hypoglycemia in
children who have had recent exposure to sulfhydryl
group containing medications.
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